Q3 Earnings Alert! Plan early for this week’s stock reports with all key data in 1 placeSee list

Baby formula shortage could ease as Abbott reopens Michigan plant

Published 06/04/2022, 11:54 AM
Updated 06/04/2022, 04:51 PM
© Reuters. FILE PHOTO: The Abbott Laboratories facility where dozens of recalled types of powdered baby formulas were made leading to production being halted at the location in Sturgis, Michigan, U.S., May 20, 2022. Picture taken with a drone.  REUTERS/Eric Cox
DANOY
-

(Reuters) -Abbott Laboratories said on Saturday that it has reopened its baby formula production plant in Sturgis, Michigan, taking a step toward alleviating an acute nationwide shortage that has sent parents scrambling for supplies.

The company said it will begin production of EleCare and other specialty and metabolic formulas, with initial EleCare product release to consumers beginning on or about June 20.

The U.S. Food and Drug Administration said on May 19 that the plant was on track to open within one or two weeks.

The facility will open after meeting initial requirements agreed to with the FDA as part of the agreement Abbott entered into on May 16, the company said.

The plant shutdown and a recall of infant formula had deepened a supply shortage in a nation where, according to federal data from 2020, less than half of babies were exclusively breast-fed through their first three months.

Roughly 73% of baby products are out of stock nationwide as of May 22, according to data firm Datasembly.

Abbott started a recall in February after reports of bacterial infections in children who had consumed the formula made at the plant.

The FDA's inspection of the Sturgis facility revealed "shocking" results such as cracks in vital equipment, a lack of adequate hand-washing and evidence of previous bacterial contamination.

Abbott has said there is no evidence to link its formulas to the illnesses, while the FDA's inspection found bacteria in environmental testing and not in the product samples.

The FDA subsequently entered into a consent decree agreement that gave it oversight of Abbott's actions to address problems at the plant.

Before the recall, Abbott controlled 40% of the infant formula market, including Similac, but the market share of other companies such as Reckitt Benckiser Group PLC has grown since then.

© Reuters. FILE PHOTO: The Abbott Laboratories facility where dozens of recalled types of powdered baby formulas were made leading to production being halted at the location in Sturgis, Michigan, U.S., May 20, 2022. Picture taken with a drone.  REUTERS/Eric Cox/File Photo

Even after the plant reopens, it may take weeks before formula supplies are back to normal, FDA Commissioner Robert Califf has said.

Global companies that make baby formula such as Neocate maker Danone SA (OTC:DANOY) are bringing products into the United States after the country's health regulator relaxed its import policy.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.